Akebia Therapeutics (AKBA) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending the European Commission to approve XOANACYL for the treatment of concomitant elevated serum phosphorous and iron deficiency in adult patients with chronic kidney disease. The EC will review the recommendation, and a final decision is expected in approximately two months.
Averoa licensed the rights to develop and commercialize ferric citrate from Akebia in the European Economic Area and certain countries in Europe and the Middle East.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.